The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
When I look back on 2018, I see tremendous growth and progress in the field of NETs and in NETRF. We are proud of our
2018 was off to a game-changing start when the FDA approved Lutetium 177 dotatate for gastrointestinal and pancreatic NETs—the first PRRT radiopharmaceutical approved in the United States.
NETRF has launched a $10 million fundraising campaign, the largest of its kind in our history. Every gift we receive will be MATCHED, doubling our
Research Aimed at Expanding Effective Treatment Options for Neuroendocrine Tumors The Neuroendocrine Tumor Research Foundation, Boston, MA, the leading funder of neuroendocrine tumor (NET) research,